AEGiS-FDA: Tentative approval of generic lamivudine tablets, 150 mg and 300 mg

Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.

Tentative approval of generic lamivudine tablets, 150 mg and 300 mg

Food and Drug Administration - August 11, 2009
Richard Klein & Kimberly Struble

On August 6, 2009, FDA granted tentative approval for a generic formulation of lamivudine tablets, 150 mg and 300 mg, manufactured by Strides Arcolab Limited of Bangalore, India, indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. The application was reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR).

"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for consideration for purchase outside the United States under the PEPFAR program.

As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.

This product is a generic formulation of Epivir tablets, 150 mg and 300 mg, a Nucleoside Reverse Transcriptase Inhibitor (NRTI) manufactured by GlaxoSmithKline. Patent and exclusivity Information about this product is available in the FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>.

You can find a complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan on the FDA web site <http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersFore ignOffices/AsiaandAfrica/ucm119231.htm>.

Richard Klein

Office of Special Health Issues

Food and Drug Administration

Kimberly Struble

Division of Antiviral Drug Products

Food and Drug Administration
090811
FD090805

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .